NCT02039765View on ClinicalTrials.gov

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
Hyperemia
Interventions
DRUG

Brimonidine tartrate

Trial Locations (1)

14609

Bausch & Lomb, Incorporated, Rochester

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT02039765 - Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%. | Biotech Hunter | Biotech Hunter